The popularity of Sildenafil initially fueled a surge for pharma, nevertheless recent changes present a complicated outlook for those considering a stake. Generic alternatives are reducing revenue, and persistent patent challenges add additional difficulty to the landscape. While certain companies might still see gains from related products, the ge